

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number 049116/296234

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	59	Office Action for Canadian Application No. 2,530,632, dated August 12, 2010; 5 pages	
	60	HACHE, M., et al; "Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery"; Journal of Thoracic and Cardiovascular Surgery; 125(1); March 1, 2003; pp 642-649	
	61	KEMMING, G., et al; "Searching for the Ideal Inhaled Vasodilator: From Nitric Oxide to Prostacyclin"; European Surgical Research; 34; 2002; pp. 196-202.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Submitted: December 9, 2010